|
WO2021026150A1
|
|
Methods for the treatment of apoc3-related diseases and disorders
|
|
WO2020247774A1
|
|
Methods for the treatment of alpha-1 antitrypsin deficiency (aatd)
|
|
WO2020163747A1
|
|
Rnai agents for hepatitis b virus infection
|
|
WO2020146521A2
|
|
Rnai agents for inhibiting expression of hif-2 alpha (epas1), compositions thereof, and methods of use
|
|
CA3109553A1
|
|
Rnai agents for inhibiting expression of 17beta-hsd type 13 (hsd17b13), compositions thereof, and methods of use
|
|
EP3784267A1
|
|
Integrin targeting ligands and uses thereof
|
|
WO2019210200A1
|
|
Integrin targeting ligands and uses thereof
|
|
AU2019220739A1
|
|
Trialkyne linking agents and methods of use
|
|
KR20200083523A
|
|
Integrin ligands and uses thereof
|
|
AR113454A1
|
|
IARN AGENTS AND COMPOSITIONS TO INHIBIT RECIPIENT EXPRESSION OF ASIALOGLYCOPROTEIN 1
|
|
CN111212909A
|
|
RNAi agents and compositions for inhibiting expression of asialoglycoprotein receptor 1
|
|
CR20200117A
|
|
Rnai agents and compositions for inhibiting expression of angiopoietin-like 3 (angptl3), and methods of use
|
|
CN111343994A
|
|
RNAi agents and compositions for inhibiting expression of angiopoietin-like 3(ANGPTL3) and methods of use
|
|
KR20200044013A
|
|
RNAi agents and compositions for inhibiting expression of apolipoprotein C-III (APOC3)
|
|
KR20200024793A
|
|
RNAi Agents and Methods of Inhibiting the Expression of Alpha-ENaC
|
|
CN110234326A
|
|
Composition and method for inhibiting factor XII gene expression
|
|
KR20190075937A
|
|
Alpha-v beta-6 integrin ligand and uses thereof
|
|
TW201801748A
|
|
5'-cyclo-phosphonate modified nucleotides
|
|
CA3011946A1
|
|
Targeting ligands for therapeutic compounds
|
|
WO2018044350A1
|
|
Targeting ligands
|
